Kadcyla reduces disease recurrence by 50% in Phase III as early breast cancer adjuvant

Genentech Inc. reported additional data from the Phase III KATHERINE trial to treat early breast cancer showing that adjuvant treatment with Kadcyla ado-trastuzumab emtansine

Read the full 249 word article

User Sign In